Clinical implications of variable relative biological effectiveness in proton therapy for prostate cancer. (2nd October 2020)

• Record Type: Journal Article
• Authors: Bertolet, A.; Carabe-Fernandez, A.
• Is Part Of: Acta oncologica. Volume 59:Number 10(2020)
• Page Start: 1171
• Page End: 1177
• Publication Date: 2020-10-02
• Subjects: Oncology -- Periodicals; Cancer -- Treatment -- Periodicals; 616.992
• DOI: 10.1080/0284186X.2020.1762928
• Languages: English
• ISSNs: 0284-186X

Abstract

Abstract: Purpose: To study the potential consequences of differences in the evaluation of variable versus uniform relative biological effectiveness calculations in proton radiotherapy for prostate cancer. Methods and material: Experimental data with proton beams suggest that relative biological effectiveness increases with linear energy transfer. This relation also depends on the α / β ratio, characteristic of a tissue and a considered endpoint. Three phenomenological models (Carabe et al., Wedenberg et al. and McNamara et al.) are compared to a mechanistic model based on microdosimetry (microdosimetric kinetic model) and to the current assumption of uniform relative biological effectiveness equal to 1.1 in a prostate case. Results and conclusions: Phenomenological models clearly predict higher relative biological effectiveness values compared to microdosimetric kinetic model, that seems to approach to the constant value of 1.1 adopted in the clinics, at least for low linear energy transfer values achieved in typical prostate proton plans. All models predict a higher increase of the relative biological effectiveness-weighted dose for the prostate tumor than for the rest of structures involved due to its lower α / β ratio, even when linear energy transfer is, in general, lower in the tumor than on the surroundings tissues. Prostate cancer is, therefore, a good candidate to take advantage of variable relative biological effectiveness, especially if linear energy transfer is enhanced within the tumor. However, the discrepancies among models hinder the clinical implementation of variable relative biological effectiveness.